

November 8, 2021

PeptiGrowth Inc.

TGFβ1 inhibitor (TGFβ1 binding peptide)

Development was completed and Available from Mid-November

PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel peptide called TGFβ1 inhibitor (TGFβ1 binding peptide) which binds to TGFβ1 to inhibit its activity. We will be marketing this product from the middle of November 2021.

Background of PeptiGrowth (PG) peptide development


Conventional growth factors and cytokines used in the manufacture of regenerative medicine, cell therapy, and other products face challenges such as quality variation among production lots, safety concerns due to contamination with biological impurities, low stability, and high cost.

PeptiGrowth was established as a joint venture between Mitsubishi Corporation and PeptiDream Inc. in April, 2020 with the mission of solving these problems and contributing to the expansion of regenerative medicine and cell therapy. Since its establishment, based on a joint development agreement with PeptiDream Inc., we have been developing the numerous peptides that have the same functions as the conventional growth factors and cytokines that are chemically synthesized and completely free of animal-derived components.

About TGFβ1 inhibitor (TGFβ1 binding peptide) (Product code:PG-002)

➤ Inhibitory activity against TGFβ1 (ligand)

Existing small molecule inhibitors must enter the cell to inhibit TGFβ1 activity. On the other hand, PG-002 is a peptide that binds to and exhibits inhibitory activity against TGFβ1 (ligand), which acts outside cells. The inhibitory activity against TGFβ1 was measured by SBE Reporter Assay, and PG-002 showed 100% inhibitory activity at 10nM against 0.13nM TGFβ1 (right figure). Using the panel assay, we also confirmed that it does not inhibit other signaling pathways. We recommend using PG-002 when the neutralization of TGFβ1 is required in cell culture.



➤ Product Overview

Product name:	TGFβ1 inhibitor (TGFβ1 binding peptide)
Product Code:	PG-002
Product form:	Lyophilized
Storage conditions:	-20 °C or less
Purity:	≥95% by HPLC
Molecular weight:	2407
Size:	10 µg, 100 µg (volume per a glass vial)

*This product is for testing and research use only (RUO).

*There is a possibility that the specification would be changed.

➤ Purchase Our Product

If you would like to purchase our products, please contact us at the information below.

Development of other peptides from PeptiGrowth

We are developing a select group of alternative peptides which have equivalent function to the conventional growth factors and cytokines. In addition to the HGF Alternative Peptide (c-Met Agonist) released in August, 2021 and this TGFβ1 inhibitor (TGFβ1 binding peptide), we plan to launch the next product by the end of March, 2022. Details will be updated on our website. For customers who would like to purchase GMP compliant products as well as the above PG products in bulk please contact us using the information provided below.

Inquiry Recipient

PeptiGrowth Inc.

Website : <https://www.peptigrowth.com/en/>

TEL : +81-70-4503-1497

E-mail : contact@peptigrowth.com